3Mielcarek M,Martin PJ,Leisenring MW,et al.Graft-versus-host disease after monmyeloablative versus conventional hematopoietic stem cell transplantation[J].Blood,2003,102(3):765-762.
4Mookerjee B,Altomonte V,Vogelsang G.Salvage therapy for refractory chronic graft-Versus-host disease with my cophenolate mofetil and tacrolimus[J].Bone Marrow Transplant,1999,24(6):517-520.
5Kolb H J,et al.Graft-Versus-Leukemia effect of donor lymphocytes transfusions in marrow grafted patients[J].Blood,1995,86:2041.
6Lamb Ls,Jr Szafer F,Henslee-Downey PJ,et al.Characterization of acute bone marrow graft rection in T-cell depleted partially mismatched related donor bone marrow transplantations[J].Exp Hematol,1995,23(5):1595-1600.
7Ash RC,Horpwitz MM,Gale RP,et al.Bone marrow transplantation from related donors other than HLA-identical siblings effect of T-cell depletion[J].Bone Marrow Transplant,1991,7 (9):443-452.
9Busca A,Saroglia EM,Lanino E,et al.Mycophenolate mafetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation[J].Bone Marrow Transplant,2000,25(4):1067-1071.
1Farag SS. Chronic graft-versus-host disease., where do we go from here, Bone Marrow Transplantation. 2004, 33: 569-577.
2Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood, 1990, 75: 2459-2464.
3G rard Sock Chronic graft-versus-host disease: clinical features and grading systems, International Journal of Hematology,2004, 79,, 216-220.
4Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versushost disease, association with treatment-related mortality and relapse. Blood, 2002, 100: 406-414.
5Mookerjee B, Ahomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus, Bone Marrow Transplant, 1999, 24:517-520.
6Anderson BE, McNiff JM, Catherine Matte, et al. RecipientCD4 + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood, 2004, 104:1565-1573.
7Okamoto I, Kohno K, Tanimoto T, et al. IL-18 prevents the development of chronic graft-versus-host disease in mice. J Immunol, 2000, 164; 6067-6074.
8Zhang Y, McCormick LL, Desai SR, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma;cutaneous cytokines, chemokines, and immune cell activation.J Immunol, 2002, 168:3088-3098.
9Remberger M, Mattsson J, Hentschke P, et al. The graft versus leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. Bone marrow transplantation, 2002, 30: 761-768.
10Horowitz MM, Gale RP, Sonedel PM, et al. Graft-versus-leu-kemia reactions after BMT. Blood, 1990, 75: 555.
